MEI Pharma(US:MEIP)2025-11-14 21:30Financial Activities - Lite Strategy, Inc. closed a $100.0 million PIPE on July 22, 2025, issuing 23,216,898 shares at an offering price of $3.42 per share[133]. - The company announced a share repurchase program of up to $25.0 million effective October 29, 2025, to be financed using available working capital[131]. - The company reported cash and cash equivalents of $10.1 million and digital assets valued at $99.4 million as of September 30, 2025[173]. - Net cash used in operating activities for the three months ended September 30, 2025, was $4.5 million, a decrease from $11.5 million in 2024[174]. - Net cash provided by financing activities for the three months ended September 30, 2025, was $96.6 million from the issuance of shares[176]. Research and Development - Voruciclib, an oral CDK9 inhibitor, completed a Phase 1 trial in September 2024 but all clinical trial efforts for it were ceased as of July 22, 2024[143][144]. - The company anticipates commencing investigational research and development activities for its drug candidate pipeline during fiscal year 2026[144]. - The company is assessing pre-clinical development programs in potentially non-oncology disease indications[130]. - Voruciclib has shown dose-dependent suppression of MCL1, which is associated with poor prognosis in AML patients[146]. - Voruciclib monotherapy study completed with 40 patients, showing no dose limiting toxicities at doses up to 200 mg[155]. - In the AML cohort, 1 patient achieved a morphologic leukemia-free state and 9 had disease stabilization lasting at least 3 months[156]. - In combination with venetoclax, 31% of patients achieved disease control at doses ≥ 100 mg, with responses lasting up to 9 months[158]. - Zandelisib development was terminated globally due to regulatory guidance, with no ongoing clinical trials[163][165]. - The company anticipates conducting additional investigational research and development activities during fiscal year 2026[173]. Expenses and Financial Management - Research and development expenses decreased by $3.2 million to $10,000 for the three months ended September 30, 2025, compared to $3.16 million in 2024[167][169]. - General and administrative expenses decreased by $2.1 million to $3.1 million for the three months ended September 30, 2025, primarily due to reduced personnel costs[170]. Strategic Initiatives - The Litecoin Treasury Strategy was initiated in August 2025, focusing on acquiring LTC tokens to diversify reserves and enhance capital efficiency[132][136]. - The company has entered into various agreements with advisors to help deploy its Litecoin Treasury Strategy, including a placement agency agreement and an asset management agreement[134]. - The evaluation of strategic alternatives included the potential for out-licensing opportunities or sale of existing programs[135]. - The company is committed to long-term innovation in capital structure and financial technology, including potential LTC mining activities[136]. Accounting and Compliance - The company has no changes in significant accounting policies or critical accounting estimates since June 30, 2025, except for those related to Digital Assets and Warrants[178]. - A 10% increase in historical volatility would have resulted in a $0.7 million increase in the grant date fair value of the Advisory Warrants[181]. - A 10% increase in assets under management would have led to a $0.2 million increase in the fair value of liabilities settled through the issuance of GSR Pre-Funded Warrants[182]. - The company has payment obligations under remaining license agreements contingent upon achieving specified development, regulatory, and commercial milestones[180]. - The company recognizes an asset for services not yet rendered and amortizes the fair value over the requisite service period[181]. - The company is obligated to reimburse clinical trial costs under future collaboration agreements, if any[180]. - The company has costs associated with securing manufacturing arrangements for development activities and commercial production[180]. - The company is required to make royalty payments in connection with the sales of products developed under license agreements[180]. - The company discusses critical accounting estimates in its Management's Discussion and Analysis section of the 2025 Annual Report[178]. - The company evaluates equity instruments issued for services based on fair value determined using an option pricing model or the fair value of liabilities incurred[179].